with neurostar advanced therapy, neuronetics, inc., is the market leader in transcranial magnetic stimulation technology for the treatment of major depressive disorder. based in malvern, pa, we are a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using mri-strength magnetic field pulses. we are the first company to have a non-systemic and non-invasive depression treatment cleared by the fda for patients who have not benefited from prior antidepressant medication. neuronetics markets neurostar advanced therapy throughout the united states and select markets around the world. if you have questions or comments about neurostar, please e-mail us at customersupport@neuronetics.com. for u.s. phone support, please call us at (877) 600-7555, for international customers, our number is +1 (610) 640-4207.
Company profile
Ticker
STIM
Exchange
Website
CEO
Keith J. Sullivan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NEURONETICS INC
SEC CIK
STIM stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
8-K
Departure of Directors or Certain Officers
28 Mar 24
8-K
Other Events
25 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Departure of Directors or Certain Officers
6 Mar 24
8-K
Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results
5 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results
8 Jan 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
Transcripts
STIM
Earnings call transcript
2023 Q4
5 Mar 24
STIM
Earnings call transcript
2023 Q3
7 Nov 23
STIM
Earnings call transcript
2023 Q2
8 Aug 23
STIM
Earnings call transcript
2023 Q1
13 May 23
STIM
Earnings call transcript
2023 Q1
9 May 23
STIM
Earnings call transcript
2022 Q4
7 Mar 23
STIM
Earnings call transcript
2022 Q3
11 Nov 22
STIM
Earnings call transcript
2022 Q2
2 Aug 22
STIM
Earnings call transcript
2022 Q1
12 May 22
STIM
Earnings call transcript
2021 Q4
8 Mar 22
Latest ownership filings
SC 13G
Divisadero Street Capital Management, LP
1 Apr 24
4
WILLIAM ANDREW MACAN
1 Mar 24
4
Stephen Furlong
1 Mar 24
4
Stephen Furlong
29 Feb 24
144
Notice of proposed sale of securities
29 Feb 24
4
Keith J Sullivan
28 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
144
Notice of proposed sale of securities
27 Feb 24
4
Keith J Sullivan
26 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 35.85 mm | 35.85 mm | 35.85 mm | 35.85 mm | 35.85 mm | 35.85 mm |
Cash burn (monthly) | 3.35 mm | 3.15 mm | 2.96 mm | 2.82 mm | 3.37 mm | 3.10 mm |
Cash used (since last report) | 22.36 mm | 21.04 mm | 19.72 mm | 18.81 mm | 22.51 mm | 20.69 mm |
Cash remaining | 13.49 mm | 14.81 mm | 16.13 mm | 17.03 mm | 13.34 mm | 15.16 mm |
Runway (months of cash) | 4.0 | 4.7 | 5.5 | 6.0 | 4.0 | 4.9 |
Institutional ownership, Q2 2023
65.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 70 |
Opened positions | 8 |
Closed positions | 13 |
Increased positions | 14 |
Reduced positions | 28 |
13F shares | Current |
---|---|
Total value | 36.65 bn |
Total shares | 19.55 mm |
Total puts | 3.90 k |
Total calls | 400.00 |
Total put/call ratio | 9.8 |
Largest owners | Shares | Value |
---|---|---|
Cannell Capital | 2.77 mm | $5.95 bn |
Archon Capital Management | 2.45 mm | $5.26 bn |
Vanguard | 1.35 mm | $2.91 bn |
Balyasny Asset Management | 1.30 mm | $2.79 bn |
SAMG Silvercrest Asset Management | 1.13 mm | $2.43 bn |
Schroder Investment Management | 944.88 k | $2.03 bn |
Flynn James E | 919.00 k | $10.21 mm |
Parian Global Management | 760.41 k | $0.00 |
Kent Lake Capital | 706.35 k | $1.52 bn |
First Eagle Investment Management | 580.18 k | $1.25 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Feb 24 | Furlong Stephen | Common Stock | Grant | Acquire A | No | No | 0 | 15,000 | 0.00 | 498,776 |
29 Feb 24 | Macan William Andrew | Common Stock | Grant | Acquire A | No | No | 0 | 15,000 | 0.00 | 404,333 |
29 Feb 24 | Macan William Andrew | Common Stock | Sell | Dispose S | No | No | 2.94 | 6,026 | 17.72 k | 389,333 |
28 Feb 24 | Macan William Andrew | Common Stock | Sell | Dispose S | No | No | 3.16 | 22,377 | 70.71 k | 395,359 |
28 Feb 24 | Furlong Stephen | Common Stock | Sell | Dispose S | No | No | 3.16 | 3,985 | 12.59 k | 483,776 |
27 Feb 24 | Furlong Stephen | Common Stock | Sell | Dispose S | No | No | 3.33 | 21,272 | 70.84 k | 487,761 |
26 Feb 24 | Sullivan Keith J | Common Stock | Sell | Dispose S | No | No | 3.3 | 20,292 | 66.96 k | 1,372,278 |
23 Feb 24 | Sullivan Keith J | Common Stock | Sell | Dispose S | No | No | 3.23 | 20,750 | 67.02 k | 1,392,570 |
22 Feb 24 | Sullivan Keith J | Common Stock | Sell | Dispose S | No | No | 3.23 | 20,851 | 67.35 k | 1,413,320 |
News
Neuronetics, Inc. Announces New Publication In Brain Stimulation Confirms Full TMS Treatment Course Is Vital
10 Apr 24
Top 5 Health Care Stocks That May Plunge In March
28 Mar 24
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
25 Mar 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
25 Mar 24
Neuronetics Q4 GAAP EPS $(0.19) Beats $(0.26) Estimate, Sales $20.31M Beat $19.85M Estimate
5 Mar 24
Press releases
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
10 Apr 24
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
27 Mar 24
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
25 Mar 24
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
7 Mar 24
Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results
5 Mar 24